Title
Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003
Date Issued
15 March 2008
Access level
open access
Resource Type
journal article
Author(s)
Morgan J.
Sperling L.
Schieber R.A.
Heffelfinger J.D.
Casey C.G.
Miller J.W.
Santibanez S.
Herwaldt B.
Hightower P.
Moro P.L.
Hibbs B.F.
Levine N.H.
Chapman L.E.
Iskander J.
Lane J.M.
Wharton M.
Mootrey G.T.
Swerdlow D.L.
Emory University School of Medicine
Abstract
Myocarditis was reported after smallpox vaccination in Europe and Australia, but no association had been reported with the US vaccine. We conducted surveillance to describe and determine the frequency of myocarditis and/or pericarditis (myo/pericarditis) among civilians vaccinated during the US smallpox vaccination program between January and October 2003. We developed surveillance case definitions for myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination. We identified 21 myo/pericarditis cases among 37,901 vaccinees (5.5 per 10,000); 18 (86%) were revacinees, 14 (67%) were women, and the median age was 48 years (range, 25-70 years). The median time from vaccination to onset of symptoms was 11 days (range, 2-42 days). Myo/pericarditis severity was mild, with no fatalities, although 9 patients (43%) were hospitalized. Three additional vaccinees were found to have dilated cardiomyopathy, recognized within 3 months after vaccination. We describe an association between smallpox vaccination, using the US vaccinia strain, and myo/pericarditis among civilians. © 2008 by the Infectious Diseases Society of America. All rights reserved.
Volume
46
Issue
SUPPL. 3
Language
English
OCDE Knowledge area
Virología
Sistema cardiaco, Sistema cardiovascular
Enfermedades infecciosas
DOI
Scopus EID
2-s2.0-41649088263
PubMed ID
Source
Clinical Infectious Diseases
ISSN of the container
10584838
Sponsor(s)
Supplement sponsorship. This article was published as part of a supplement entitled “Posteradication Vaccination against Smallpox,” sponsored by the National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), and by the Coordinating Office for Terrorism Prevention and Emergency Response, CDC. Potential conflicts of interest. All authors: no conflicts.
Sources of information:
Directorio de Producción Científica
Scopus